P J Maguire1, M McGuire2, K A Power2, M McNicholl2, S R Sheehan2, M J Turner2. 1. UCD Centre for Human Reproduction, Coombe Women and Infants University Hospital, Dublin 8, Ireland. pmaguire7@gmail.com. 2. UCD Centre for Human Reproduction, Coombe Women and Infants University Hospital, Dublin 8, Ireland.
Abstract
BACKGROUND: National guidelines have been developed to ensure correct dosing of tinzaparin for women delivered by caesarean delivery (CD) to reduce the risk of venous thromboembolism. AIMS: The aim of this study is to examine the impact of implementation of national guidelines on thromboprophylaxis prescribing practice for women undergoing CD in a university maternity hospital. METHODS: Details of tinzaparin usage were obtained from the Hospital pharmacy for the years 2009-2014. Information on CD and pulmonary embolism (PE) were obtained from the Hospital's annual clinical reports. RESULTS: Following guideline recommendations on weight-based tinzaparin for all women undergoing CD, the usage of syringes prefilled with tinzaparin 4500 IU increased from 526 to 8502 (P < 0.001) and usage of syringes prefilled with tinzaparin 10,000 IU increased from 36 to 910 (P < 0.001). Usage of syringes prefilled with tinzaparin 3500 IU decreased from 8216 in 2009 to 39 in 2014 (P < 0.001). During 2008-2010, there were two cases of PE after CD, both of whom received an inadequate dose of prophylactic tinzaparin. During 2011-2014 there were no cases of PE diagnosed after a total of 9427 CDs. CONCLUSIONS: The development of national guidelines on thromboprophylaxis after CD was followed by a significant change in weight-based prescribing of tinzaparin. Following implementation, there have been no cases of PE after CD.
BACKGROUND: National guidelines have been developed to ensure correct dosing of tinzaparin for women delivered by caesarean delivery (CD) to reduce the risk of venous thromboembolism. AIMS: The aim of this study is to examine the impact of implementation of national guidelines on thromboprophylaxis prescribing practice for women undergoing CD in a university maternity hospital. METHODS: Details of tinzaparin usage were obtained from the Hospital pharmacy for the years 2009-2014. Information on CD and pulmonary embolism (PE) were obtained from the Hospital's annual clinical reports. RESULTS: Following guideline recommendations on weight-based tinzaparin for all women undergoing CD, the usage of syringes prefilled with tinzaparin 4500 IU increased from 526 to 8502 (P < 0.001) and usage of syringes prefilled with tinzaparin 10,000 IU increased from 36 to 910 (P < 0.001). Usage of syringes prefilled with tinzaparin 3500 IU decreased from 8216 in 2009 to 39 in 2014 (P < 0.001). During 2008-2010, there were two cases of PE after CD, both of whom received an inadequate dose of prophylactic tinzaparin. During 2011-2014 there were no cases of PE diagnosed after a total of 9427 CDs. CONCLUSIONS: The development of national guidelines on thromboprophylaxis after CD was followed by a significant change in weight-based prescribing of tinzaparin. Following implementation, there have been no cases of PE after CD.
Entities:
Keywords:
Clinical guideline implementation; Low molecular weight heparin; Maternal medicine
Authors: Nils Chaillet; Eric Dubé; Marylène Dugas; François Audibert; Caroline Tourigny; William D Fraser; Alexandre Dumont Journal: Obstet Gynecol Date: 2006-11 Impact factor: 7.661
Authors: Menaka Pai; Nancy S Lloyd; Ji Cheng; Lehana Thabane; Frederick A Spencer; Deborah J Cook; R Brian Haynes; Holger J Schünemann; James D Douketis Journal: Implement Sci Date: 2013-01-02 Impact factor: 7.327